Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.35 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12292281 | 1.00 | TDP1 (0.47) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL991815 | 0.92 | TDP1 (0.54) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL23796907 | 0.90 | MAOA (0.52) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL23796908 | 0.90 | MAOA (0.52) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL12155283 | 0.89 | TDP1 (0.47) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL20191171 | 0.89 | TDP1 (0.47) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL20122294 | 0.89 | TDP1 (0.47) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL12514747 | 0.88 | TDP1 (0.44) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL18262806 | 0.88 | TDP1 (0.44) | TDP1MAOAMAOBCA1CA2 | |
| SCHEMBL1795152 | 0.88 | TDP1 (0.44) | TDP1MAOAMAOBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371350-B2 | Trehalose derivatives and pharmaceutical compositions for treating neurodegenerative diseases | POSTECH FOUNDATION (KR) | 2016-06-21 | — | — | US | disclosed |
| US-20150025035-A1 | INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2015-01-22 | — | — | US | disclosed |
| US-8058413-B2 | Molecular transporters based on sugar and its analogues and processes for the preparation thereof | POSTECH FOUNDATION (KR) | 2011-11-15 | — | — | US | disclosed |
| US-20110224423-A1 | INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2011-09-15 | — | — | US | disclosed |
| US-20100330671-A1 | MOLECULAR TRANSPORTERS BASED ON SUGAR AND ITS ANALOGUES AND PROCESSES FOR THE PREPARATION THEREOF | POSTECH FOUNDATION (KR) | 2010-12-30 | — | — | US | disclosed |
| US-7846975-B2 | Molecular transporters based on sugar and its analogues and processes for the preparation thereof | POSTECH FOUNDATION (KR) | 2010-12-07 | — | — | US | disclosed |
| US-20080249296-A1 | Molecular Transporters Based on Sugar and Its Analogues and Processes For the Preparation Thereof | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224423-A1 | INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME | HTT, TREH, ITPA | TDP1 200/4885MAOA 2060/4885MAOB 1806/4885 |
| US-20080249296-A1 | Molecular Transporters Based on Sugar and Its Analogues and Processes For the Preparation Thereof | SLC2A1, SLC2A8, SLC2A2 | TDP1 4468/4885MAOA 4440/4885MAOB 3850/4885 |
| US-20150025035-A1 | INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME | HTT, TREH, ITPA | TDP1 200/4885MAOA 2060/4885MAOB 1806/4885 |
| US-20100330671-A1 | MOLECULAR TRANSPORTERS BASED ON SUGAR AND ITS ANALOGUES AND PROCESSES FOR THE PREPARATION THEREOF | SLC2A1, SLC2A8, SLC2A2 | TDP1 4468/4885MAOA 4440/4885MAOB 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.